当前位置: X-MOL 学术Ther. Adv. Med. Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08–10 trial
Therapeutic Advances in Medical Oncology ( IF 4.9 ) Pub Date : 2019-07-24 , DOI: 10.1177/1758835919864236
Giuseppe Gullo 1 , Alex J Eustace 2 , Alexandra Canonici 2 , Denis M Collins 2 , Michael J Kennedy 3 , Liam Grogan 4 , Oscar Breathhnach 4 , John McCaffrey 5 , Maccon Keane 6 , Michael J Martin 7 , Rajnish Gupta 8 , Gregory Leonard 6 , Miriam O'Connor 9 , Paula M Calvert 9 , Paul Donnellan 6 , Janice Walshe 10 , Enda McDermott 10 , Kathleen Scott 11 , Andres Hernando 11 , Imelda Parker 11 , David W Murray 12 , Alice C O'Farrell 12 , Ashwini Maratha 13 , Patrick Dicker 14 , Mairin Rafferty 13 , Verena Murphy 11 , Norma O'Donovan 2 , William M Gallagher 13 , Bonnie Ky 15 , Dimitrios Tryfonopoulos 10 , Brian Moulton 16 , Annette T Byrne 12 , John Crown 10
Affiliation  

Angiogenesis is one of the hallmarks of cancer, and anti-angiogenic drugs have been the focus of intense study in clinical trials. Vascular endothelial growth factor (VEGF) occupies a central regulatory role in the process of angiogenesis. High levels of circulating VEGF predict a poor prognosis in cancer patients.1 The VEGF family consists of several signal protein variants and their receptors. Among them, the interaction between VEGF-A and VEGF receptor (VEGFR) subtype 2 is predominant in the formation of new blood vessels. Several studies have found a significant correlation between VEGF expression and clinical outcome in breast cancer (BC), with disease-free survival (DFS) and overall survival (OS) being significantly worse among those patients who have cancers overexpressing VEGF.2 Micro-metastases seem to depend on angiogenesis,3 therefore, targeting the anti-angiogenic switch before tumour vascularization, in the adjuvant setting when few pro-angiogenic factors are involved, has been hypothesized as an appropriate setting for anti-angiogenic therapy.

中文翻译:

贝伐单抗联合多西他赛和环磷酰胺作为早期 HER-2 阴性乳腺癌患者辅助治疗的初步研究,包括分析心脏毒性的候选循环标志物:ICORG 08-10 试验

血管生成是癌症的标志之一,而抗血管生成药物一直是临床试验中深入研究的重点。血管内皮生长因子(VEGF)在血管生成过程中起着重要的调节作用。高水平的循环 VEGF 预示着癌症患者的不良预后。1 VEGF 家族由几种信号蛋白变体及其受体组成。其中,VEGF-A 和 VEGF 受体 (VEGFR) 亚型 2 之间的相互作用在新血管的形成中占主导地位。几项研究发现,VEGF 表达与乳腺癌 (BC) 临床结果之间存在显着相关性,在过度表达 VEGF 的癌症患者中,无病生存期 (DFS) 和总生存期 (OS) 明显更差。2微转移似乎依赖于血管生成,3因此,在肿瘤血管化之前靶向抗血管生成开关,在涉及很少促血管生成因子的辅助环境中,已被假设为抗血管生成治疗的合适环境。
更新日期:2019-07-24
down
wechat
bug